New psoriasis pill shows promise in major trial
NCT ID NCT07326813
First seen Jan 08, 2026 · Last updated May 23, 2026 · Updated 19 times
Summary
This study tests a new oral drug, D-2570, in 477 adults with moderate to severe plaque psoriasis. Participants will receive either D-2570, a placebo, or an active comparator to see how well it clears skin and improves quality of life. The trial is double-blind, meaning neither patients nor doctors know who gets which treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Skin Disease Hospital
RECRUITINGShanghai, Shanghai Municipality, 200443, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.